Moderna

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2010-01-01

Employees: 5.6K

Market Cap: $30.3B

Website: http://www.modernatx.com

Introduction: Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Clinical Trials

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Phase 1

Recruiting

Conditions: Cytomegalovirus

Interventions: Other: Placebo
Biological: mRNA-1647

First Posted Date: 2022-10-12

Last Posted Date: 2025-07-01

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 860

Registration Number: NCT05575492

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Paradigm Clinical Research Institute Inc - ClinEdge - PPDS, La Mesa, California, United States
🇺🇸
Velocity Clinical Research - San Diego - PPDS, La Mesa, California, United States

and more 68 locations

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: Placebo
Biological: mRNA-1345

First Posted Date: 2022-10-10

Last Posted Date: 2025-01-24

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 10994

Registration Number: NCT05572658

Locations: 🇺🇸
Accel Research Site - Achieve - Birmingham - ERN - PPDS, Birmingham, Alabama, United States
🇺🇸
AES - DRS - Simon Williamson Clinic, PC - Birmingham, Birmingham, Alabama, United States
🇺🇸
Lakeview Clinical Research, Guntersville, Alabama, United States

and more 103 locations

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Phase 3

Completed

Conditions: Seasonal Influenza

Interventions: Biological: mRNA-1010
Biological: Licensed quadrivalent inactivated seasonal influenza vaccine
Biological: Fluarix Quadrivalent

First Posted Date: 2022-10-04

Last Posted Date: 2025-01-16

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 22502

Registration Number: NCT05566639

Locations: 🇺🇸
North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸
Lenzmeier Family Medicine, Glendale, Arizona, United States
🇺🇸
CCT Research, Las Vegas, Nevada, United States

and more 218 locations

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Biological: mRNA-4359
Biological: Pembrolizumab

First Posted Date: 2022-09-09

Last Posted Date: 2025-03-10

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 194

Registration Number: NCT05533697

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
George Washington University, Washington, District of Columbia, United States

and more 23 locations

Use of Wearable Digital Sensors After mRNA Vaccination in Adults

Completed

Conditions: Healthy Participants

Interventions: Device: Wireless wearable digital devices

First Posted Date: 2022-06-30

Last Posted Date: 2023-04-04

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 62

Registration Number: NCT05440318

Locations: 🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States
🇺🇸
Meridian Clinical Research, Lincoln, Nebraska, United States
🇺🇸
Benchmark Research, Austin, Texas, United States

and more 1 locations

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Phase 3

Recruiting

Conditions: SARS-CoV-2

Interventions: Biological: mRNA-1273.214
Biological: mRNA-1273.815

First Posted Date: 2022-06-29

Last Posted Date: 2025-03-10

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 1860

Registration Number: NCT05436834

Locations: 🇦🇷
AES - AS - Glenny Corp. S.A. Buenos Aires, Caba, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Ciudad Autónoma de Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina
🇦🇷
AES - AS - Clinica Mayo de Urgencias, San Miguel de Tucumán, Tucumán, Argentina

and more 62 locations

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Phase 3

Completed

Conditions: Seasonal Influenza

Interventions: Biological: mRNA-1010
Biological: Fluarix Tetra

First Posted Date: 2022-06-13

Last Posted Date: 2023-09-13

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 6102

Registration Number: NCT05415462

Locations: 🇦🇷
CEI -Centro de Estudios Infectológicos, Buenos Aires, Argentina
🇦🇷
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Ciudad Autonoma Buenos Aires, Argentina
🇦🇷
Swiss Medical Center Barrio Parque, Ciudad Autónoma Buenos Aires, Argentina

and more 50 locations

A Study of Modified mRNA Vaccines in Healthy Adults

Phase 1

Active, not recruiting

Conditions: SARS-CoV-2
Respiratory Syncytial Virus
Cytomegalovirus
Seasonal Influenza

Interventions: Biological: mRNA-1345
Biological: mRNA-1647
Biological: mRNA-1273
Biological: FLUAD®
Biological: mRNA-1010

First Posted Date: 2022-05-31

Last Posted Date: 2025-03-24

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 308

Registration Number: NCT05397223

Locations: 🇺🇸
CenExel, Hollywood, Florida, United States
🇺🇸
Meridian Clinical Research, Lincoln, Nebraska, United States
🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States

and more 3 locations

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Phase 1

Completed

Conditions: SARS-CoV-2
Influenza

Interventions: Biological: mRNA-1273
Biological: mRNA-1010
Biological: mRNA-1073
Biological: Placebo

First Posted Date: 2022-05-17

Last Posted Date: 2024-02-28

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 550

Registration Number: NCT05375838

Locations: 🇺🇸
Research Centers of America, Hollywood, Florida, United States
🇺🇸
AES - DRS - Optimal Research Illinois - Peoria, Peoria, Illinois, United States
🇺🇸
Meridian, Cincinnati, Ohio, United States

and more 5 locations

A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind

Completed

Conditions: SARS-CoV-2

First Posted Date: 2022-05-10

Last Posted Date: 2022-10-13

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 1501

Registration Number: NCT05367908

Locations: 🇺🇸
Evidation Health, San Mateo, California, United States

AI-Powered Research

Premium Access

Moderna

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Use of Wearable Digital Sensors After mRNA Vaccination in Adults

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

A Study of Modified mRNA Vaccines in Healthy Adults

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind